TherapeuticsMD, Inc. - TXMD STOCK NEWS

TherapeuticsMD (NASDAQ:TXMD) announced FDA approval for a supplemental New Drug Application for ANNOVERA, marking a significant milestone for the company. This approval allows for a reduction in manufacturing batch rejections and an increase in product supply, enabling an additional 7,000 rings to meet short- and long-term demand. Since its initial approval in August 2018, ANNOVERA remains the only FDA-approved, procedure-free, long-lasting reversible birth control option.

TherapeuticsMD (TXMD) reported Q1 2022 net product revenue of $19.3 million, a decrease from $19.9 million in Q1 2021. Despite ANNOVERA experiencing manufacturing challenges, prescriptions rose by 27% to 8,014. The divestiture of vitaCare for $150 million was completed in just five weeks. However, the net loss for the quarter was $49 million, or $5.69 per share. Cash on hand decreased significantly to $30.4 million from $65.1 million at the end of 2021. The company aims for improved performance moving forward.

TherapeuticsMD, Inc. (TXMD) will announce its first quarter 2022 financial results on May 16, 2022, after U.S. market close. An executive management conference call is scheduled for 4:30 p.m. ET on the same day. Investors can access the live webcast on the company's website, with a digital recording available for replay afterward. TherapeuticsMD focuses on women's healthcare, offering innovative products in family planning and menopause management. The company emphasizes its commitment to advancing women's health.

TherapeuticsMD (NASDAQ: TXMD) has successfully completed the $150 million divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX). This strategic move, initially announced on March 6, 2022, allows TXMD to concentrate on its women's health portfolio. The company could also receive an additional $7 million based on vitaCare's 2023 financial performance. CEO Hugh O’Dowd emphasized the importance of this transaction in enhancing value for shareholders and patients.

TherapeuticsMD, Inc. (TXMD) has reached a definitive agreement to divest its vitaCare business unit, allowing the company to concentrate on women's healthcare. CEO Hugh O’Dowd stated this move supports their goal to empower women through affordable healthcare solutions. In Q4 2021, TXMD reported total revenue of $18.7 million, down from $22.6 million in Q4 2020, driven by decreased sales of ANNOVERA and IMVEXXY. Net loss for the quarter was $43 million, or $0.10 per share. The company amended credit terms to enhance financial flexibility. Conference call scheduled for 8:30 a.m. ET today.

TherapeuticsMD has agreed to divest its vitaCare Prescription Services business to GoodRx for $150 million in cash, plus up to $7 million contingent on vitaCare's 2023 performance. The deal is set to close in Q2 2022, allowing TXMD to focus on its core women's health business. CEO Hugh O’Dowd expressed confidence in GoodRx's ability to enhance patient access. TXMD will discuss this transaction in its earnings call on March 10, 2022.

TherapeuticsMD, Inc. (NASDAQ: TXMD) will report its Q4 2021 financial results on March 10, 2022, before the U.S. markets open. Executive management will hold a conference call and webcast at 8:30 a.m. ET to discuss the results.

Interested parties can access the conference via a toll-free number or through a webcast link provided. A replay will be available for 30 days on the company's website.

Galderma, the largest independent dermatology company, announced the appointment of Karen L. Ling to its Advisory Committee, effective March 1, 2022. Ms. Ling brings over 25 years of global human resources experience from executive positions at AIG, Allergan, Merck, and Wyeth, focusing on talent management and organizational culture. Currently, she serves on the Boards of iRhythm Technologies (NASDAQ: IRTC) and TherapeuticsMD (NASDAQ: TXMD). Both Thomas Ebeling and Flemming Ørnskov expressed enthusiasm about her joining, highlighting her strengths in human capital management and diversity initiatives.

TherapeuticsMD, Inc. (NASDAQ:TXMD) announced that the FDA denied proposed revisions to the manufacturing testing limits for ANNOVERA through a Supplemental New Drug Application (sNDA). The FDA provided recommendations for further information to support future revisions. As a result, the company will continue to supply ANNOVERA under the existing manufacturing specifications approved in its original NDA. ANNOVERA is recognized as a long-lasting, reversible birth control option approved by the FDA in August 2018.